Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
12.85
-0.34 (-2.58%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Apollomics Employees
Apollomics had 13 employees as of December 31, 2024. The number of employees decreased by 32 or -71.11% compared to the previous year.
Employees
13
Change (1Y)
-32
Growth (1Y)
-71.11%
Revenue / Employee
$691,846
Profits / Employee
-$841,462
Market Cap
27.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -32 | -71.11% |
| Dec 31, 2023 | 45 | 2 | 4.65% |
| Dec 31, 2022 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Kyntra Bio | 34 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Lantern Pharma | 16 |
| Tvardi Therapeutics | 12 |
| Neuphoria Therapeutics | 8 |
APLM News
- 1 day ago - Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewsWire
- 27 days ago - Apollomics Inc. Announces $2.0 Million Bridge Financing - GlobeNewsWire
- 4 months ago - Apollomics Reports First Half 2025 Financial Results - GlobeNewsWire
- 5 months ago - Apollomics Announces Settlement of Cayman Litigation - GlobeNewsWire
- 5 months ago - Apollomics Announces Changes to its Board of Directors and Composition of Committees - GlobeNewsWire
- 6 months ago - Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - GlobeNewsWire
- 7 months ago - Apollomics, Inc. Company Operational Continuity Update - GlobeNewsWire
- 1 year ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire